During the period spanning 2004 to 2013, the co-cited references predominantly centered around topics such as DNA methylation, histone deacetylase inhibitors, immunotherapy, and EZH2, reflecting the initial investigations into tumor epigenetic therapy. This evidence concerns the gene EZH2 and neoplasm.